Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

INTRODUCTION: The presence of high‐risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib...

Descripción completa

Detalles Bibliográficos
Autores principales: Spicka, Ivan, Moreau, Philippe, Martin, Thomas G., Facon, Thierry, Martinez, Gracia, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Risse, Marie‐Laure, Asset, Gaëlle, Macé, Sandrine, van de Velde, Helgi, Yong, Kwee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804737/
https://www.ncbi.nlm.nih.gov/pubmed/35871357
http://dx.doi.org/10.1111/ejh.13835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804737/
https://www.ncbi.nlm.nih.gov/pubmed/35871357
http://dx.doi.org/10.1111/ejh.13835

Ejemplares similares